Ensysce Biosciences Crescita futura
Future criteri di controllo 5/6
Ensysce Biosciences is forecast to grow earnings and revenue by 99.1% and 141.9% per annum respectively while EPS is expected to grow by 116.8% per annum.
Informazioni chiave
99.1%
Tasso di crescita degli utili
116.8%
Tasso di crescita dell'EPS
| Biotechs crescita degli utili | 27.1% |
| Tasso di crescita dei ricavi | 141.9% |
| Rendimento futuro del capitale proprio | n/a |
| Copertura analitica | Low |
| Ultimo aggiornamento | 24 Sep 2024 |
Aggiornamenti recenti sulla crescita futura
Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2026 | 80 | 70 | N/A | N/A | 1 |
| 12/31/2025 | N/A | -9 | N/A | N/A | 1 |
| 12/31/2024 | 1 | N/A | N/A | N/A | 1 |
| 6/30/2024 | 1 | -11 | -10 | -10 | N/A |
| 3/31/2024 | 2 | -12 | -11 | -11 | N/A |
| 12/31/2023 | 2 | -11 | -11 | -11 | N/A |
| 9/30/2023 | 3 | -13 | -12 | -12 | N/A |
| 6/30/2023 | 3 | -20 | -17 | -17 | N/A |
| 3/31/2023 | 3 | -26 | -18 | -18 | N/A |
| 12/31/2022 | 3 | -25 | -18 | -18 | N/A |
| 9/30/2022 | 3 | -30 | -18 | -18 | N/A |
| 6/30/2022 | 4 | -38 | -15 | -15 | N/A |
| 3/31/2022 | 4 | -31 | -11 | -11 | N/A |
| 12/31/2021 | 4 | -30 | -8 | -8 | N/A |
| 9/30/2021 | 2 | -19 | -5 | -5 | N/A |
| 6/30/2021 | 2 | 0 | -1 | -1 | N/A |
| 3/31/2021 | 3 | 0 | -1 | -1 | N/A |
| 12/31/2020 | 4 | 0 | -1 | -1 | N/A |
| 12/31/2019 | 2 | -10 | -1 | -1 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: ENSC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).
Guadagni vs Mercato: ENSC is forecast to become profitable over the next 3 years, which is considered above average market growth.
Guadagni ad alta crescita: ENSC is expected to become profitable in the next 3 years.
Ricavi vs Mercato: ENSC's revenue (141.9% per year) is forecast to grow faster than the US market (8.9% per year).
Ricavi ad alta crescita: ENSC's revenue (141.9% per year) is forecast to grow faster than 20% per year.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Insufficient data to determine if ENSC's Return on Equity is forecast to be high in 3 years time